Visit our customer abstracts.

 

 

 

 

 

 

Abstract 519

Loibl, S., et al. Phase III study of palbociclib combined with endocrine therapy in patients with hormone-receptor-positive, HER2-negative primary breast cancer and high relapse risk after neoadjuvant chemotherapy: First results from PENELOPE-B

Abstract 558

Lopez-Guerrero, J. A., et al. MamaPred: a new and innovative approach to determine recurrence risk classification in luminal early-stage breast cancer using HTG EdgeSeq Technology

Featured Publication

Cross-platform comparison of immune-related gene expression to assess intra tumor immune response following cancer immunotherapy

Two commonly used targeted gene expression profiling platforms are compared in this  article.
 

 READ PUBLICATION

News & Events

HTG Molecular Diagnostics to Announce Q1 2021 Financial Results and Host Conference Call on Thursday, May 13

TUCSON, Ariz. , May 04, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the quarter ended March 31, 2021 after the market close on Thursday,

Keep Reading

16th International Virtual Conference on Malignant Lymphoma

June 18 - 22, 2021| Join us at this international congress to learn more about the latest advances in the science regarding malignant lymphoma.

Posted on:

Keep Reading

2021 ASCO Virtual Scientific Meeting

June 4 - 8, 2021 | Join us at ASCO and learn about breakthrough research being presented by HTG customers.

Posted on:

Keep Reading

HTG Molecular Diagnostics Reports Preliminary First Quarter 2021 Financial Results

TUCSON, Ariz. , April 05, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported certain preliminary financial results for the first quarter ended March 31, 2021 .

Keep Reading

HTG Molecular Diagnostics Reports Full Year 2020 Results

Call scheduled for today, March 25, at 4:30pm ET TUCSON, Ariz. , March 25, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the year ended December 31, 2020

Keep Reading

HTG Molecular Diagnostics to Announce Year End 2020 Financial Results and Host Conference Call on Thursday, March 25

TUCSON, Ariz. , March 16, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the year ended December 31, 2020 after the market close on

Keep Reading

Careers at HTG

At HTG Molecular Diagnostics, Inc., we are always looking for talented individuals to help us deliver our next-generation sequencing-based products throughout the world.

Featured Positions

New Careers

Research Scientist

Summer Internships Available!

Scientist

Lab Supervisor

Director, Pharma Scientific Liaison

Senior Project Manager

See All Careers


Resources

Find product information, specifications and gene lists here. 

Case Studies

Brochures

Gene Lists

Product Sheets

Tech Notes

Safety Data Sheets

Videos


Publications

Read white papers or journal publications and view other scientific content. 

White Papers

Posters

Abstracts

Webinars

Peer Reviewed Publications

Editorials

Reviews


Support

Log in to your account to view technical manuals, package inserts, and other information related to your HTG EdgeSeq system or panels. 

Product Launch Files

User Manuals RUO

User Manuals CE-IVD

Package Inserts RUO

Package Inserts CE-IVD

Training Modules RUO

Training Modules CE-IVD

Deployer Software Downloads

HTG Software Downloads

Page last updated May 11, 2021

Ready to get started?

HTG is focused on delivering exceptional molecular profiling products and services. Contact us to find out how our unique technology can benefit you.

Get in Touch